GSK plc (GSK) Releases Q4 2025 Earnings: Revenue Up 13.8% and EPS Surges

GSK plc (GSK) reported fourth-quarter 2025 results with total revenue of $11.6 billion, representing a 13.8% year-over-year increase.

Total revenue: $11.6 billion (+13.8% YoY).

Gross profit: $11.6 billion (+66.2% YoY).

Operating profit: $11.9 billion (+1,264.7% YoY).

Net income attributable to common shareholders: $11.5 billion (+2,121.8% YoY).

Diluted earnings per share: $5.66 (+2,732.1% YoY).

Cash from operating activities: $3.6 billion (+40.7% YoY).

Purchases of property, plant and equipment (capital expenditures): $771 million (up 26.0% YoY).

Cash and cash equivalents: $4.6 billion (down 5.9% YoY).

Total liabilities: $60.7 billion (up 4.4% YoY).

Cost of sales: $3.0 billion (down 7.4% YoY).

The quarter shows meaningful margin and profitability expansion alongside solid revenue growth, supported by stronger operating cash flow. While the cash balance declined modestly, liabilities increased slightly year over year.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

GSK plc Hedge Fund Activity

We have seen 429 institutional investors add shares of GSK plc stock to their portfolio, and 404 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 5,139,956 shares (+8.4%) to their portfolio in Q3 2025, for an estimated $221,840,500
ALYESKA INVESTMENT GROUP, L.P. removed 3,156,875 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $136,250,725
WELLINGTON MANAGEMENT GROUP LLP added 1,965,611 shares (+135.1%) to their portfolio in Q3 2025, for an estimated $84,835,770
PRIMECAP MANAGEMENT CO/CA/ removed 1,959,830 shares (-7.1%) from their portfolio in Q3 2025, for an estimated $84,586,262
CLARK CAPITAL MANAGEMENT GROUP, INC. removed 1,779,776 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $76,815,132
UBS GROUP AG added 1,635,448 shares (+35.2%) to their portfolio in Q4 2025, for an estimated $80,202,369
HOLOCENE ADVISORS, LP added 1,490,889 shares (+26.6%) to their portfolio in Q3 2025, for an estimated $64,346,769

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

GSK plc Congressional Stock Trading

Members of Congress have traded $GSK stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $GSK stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.
REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 09/23.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

GSK plc Analyst Ratings

Wall Street analysts have issued reports on $GSK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Underweight" rating on 01/06/2026
Jefferies issued a "Buy" rating on 10/27/2025

To track analyst ratings and price targets for GSK plc, check out Quiver Quantitative's $GSK forecast page.